Galapagos(GLPGF)

2800 MECHELEN, Belgium

Biotechnology

Website LinkedIn Careers Page

Focus: Drug & Antibody Therapy Discovery

Galapagos is a life sciences company focused on Drug & Antibody Therapy Discovery.

ImmunologyRare DiseasesRespiratoryOncologyNephrology

Funding Stage

PUBLIC

Open Jobs

Pipeline & Clinical Trials

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT056971597 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

N/A

Intestinal ultrasound

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT05653791Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis

N/A

Synovial Biopsy

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT07000890Rheumatoid Arthritis Synovial Tissue Biopsy Study

N/A

JAK inhibitor treatment

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT05456412JAK Inhibition in Ulcerative Colitis

N/A

GLPG2451 multiple dose

Healthy

Phase 1

Clinical Trials (1)

NCT03214614A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects

Phase 1

GLPG2451 single dose

Healthy

Phase 1

Clinical Trials (1)

NCT02788721A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Phase 1

GLPG0187

Healthy

Phase 1

Clinical Trials (1)

NCT00928343First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187

Phase 1

GLPG1205

Healthy

Phase 1

Clinical Trials (1)

NCT02623296A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

Phase 1

GLPG3667 capsule

Healthy

Phase 1

Clinical Trials (1)

NCT05335447Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Phase 1

GLPG2737 single dose

Healthy

Phase 1

Clinical Trials (1)

NCT03410979A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Phase 1

GLPG1205 single ascending doses, oral suspension

Healthy

Phase 1

Clinical Trials (1)

NCT01887106First-in-Human Single and Multiple Dose of GLPG1205

Phase 1

GLPG3121

Healthy

Phase 1

Clinical Trials (1)

NCT04856358A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Phase 1

200 mg GLPG0634 as capsules, fasted

Healthy

Phase 1

Clinical Trials (1)

NCT01915667Oral Bioavailability of Two Solid Formulations of GLPG0634

Phase 1

GLPG1205

Healthy

Phase 1

Clinical Trials (1)

NCT04532567A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

Phase 1

GLPG0492

Healthy

Phase 1

Clinical Trials (1)

NCT01130818First-in-Human Single Ascending Dose of GLPG0492

Phase 1

GLPG3667

Healthy

Phase 1

Clinical Trials (1)

NCT04736927Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects

Phase 1

GLPG0634

Healthy

Phase 1

Clinical Trials (1)

NCT01179581First-in-Human Single Ascending and Multiple Dose of GLPG0634

Phase 1

GLPG1690 film-coated tablets

Healthy

Phase 1

Clinical Trials (1)

NCT03787186A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

Phase 1

GLPG2451 dose regimen A

Cystic Fibrosis

Phase 1

Clinical Trials (1)

NCT03540524A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

Phase 1

GLPG2737 single dose

Cystic Fibrosis

Phase 1

Clinical Trials (1)

NCT03450720Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Phase 1

100 mg dose of [14C] GLPG0634

Healthy

Phase 1

Clinical Trials (1)

NCT01820806Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

Phase 1

GLPG0555

Healthy

Phase 1

Clinical Trials (1)

NCT01208753Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

Phase 1

GLPG3667

Healthy

Phase 1

Clinical Trials (1)

NCT04976270A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Phase 1

GLPG1690

Healthy

Phase 1

Clinical Trials (1)

NCT03515382A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Phase 1

GLPG1972

Healthy

Phase 1

Clinical Trials (1)

NCT03143725Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution

Phase 1

GLPG0555

Healthy

Phase 1

Clinical Trials (1)

NCT01023321First-in-Human Single Ascending and Multiple Dose of GLPG0555